Paper Details

  1. Home
  2. Paper Details

Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A clinical study was undertaken in 57 patients with melanoma stage I and 37 patients with melanoma stage III. The patients were randomly assigned to receive either DTIC and BCG or observation only. Only those with stage III melanoma showed a delay in recurrence and increased survival, but the difference was not statistically significant. The control group had higher survival rates than previous studies, providing a baseline for future adjuvant melanoma treatment trials.
Paper Details　
Original Abstract of the Article :
A clinical study was undertaken in 57 patients with completely excised nodular or superficial spreading melanoma invasive to Clark's level 3, 4 or 5 (stage I) and 37 patients with completely resected in transit or lymph node metastases (stage III). The patients were randomly allocated to either a tr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1875390/

データ提供：米国国立医学図書館（NLM）

Chemoimmunotherapy for Melanoma: A Randomized Controlled Trial

Melanoma is a serious form of skin cancer. This research explores the effectiveness of chemoimmunotherapy using DTIC (dimethyltriazeno imidazole carboxamide) and BCG (bacille Calmette-Guérin) as an adjuvant treatment after complete surgical excision of melanoma. The authors conducted a randomized controlled trial involving patients with melanoma, comparing the outcomes of those who received chemoimmunotherapy to those who received only observation. The study found that chemoimmunotherapy showed a delay in recurrence and an increase in survival only in patients with stage III disease, although the improvement was not statistically significant.

Chemoimmunotherapy: A Potential Adjuvant Treatment for Melanoma

This study provides insights into the potential benefits of chemoimmunotherapy as an adjuvant treatment for melanoma. While the findings showed limited evidence of effectiveness in stage I disease, the authors observed a delay in recurrence and an increase in survival in patients with stage III melanoma, suggesting a potential role for this therapy in specific patient populations.

A Promising Avenue for Melanoma Research

This research highlights the need for further investigation into the role of chemoimmunotherapy in melanoma treatment. The authors' findings, while not conclusive, suggest a potential benefit in stage III disease, warranting further research to explore the optimal use of this therapy in different patient subgroups. It's like discovering a potential oasis of treatment options in the desert of melanoma research, encouraging further exploration and refinement of this therapeutic approach.

Dr.Camel's Conclusion

This research is a reminder that the journey to find effective treatments for melanoma is ongoing. While chemoimmunotherapy shows some promise, further research is needed to understand its true potential and optimize its use. It's like a camel navigating a sandy landscape, searching for a reliable source of water that can sustain life and bring relief from this challenging disease.

Date :
  1. Date Completed 1983-05-27
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

6339024

DOI: Digital Object Identifier

PMC1875390

Related Literature

Article Analysis
・Effective treatment of melanoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.